According to QuantRx, the RapidSense phencyclidine (PCP) test is the second of the company’s drugs-of-abuse (DOA) tests based solely on its proprietary technology cleared by the FDA.
The RapidSense PCP test is a one-step positive read lateral flow device intended for use in the professional markets.
Walter Witoshkin, chairman and CEO of QuantRx, said: “We are pleased to continue to show progress with our technology, with this additional clearance for our proprietary DOA tests. This continues to show that our RapidSense technology will bring significant innovation to the broad US marketplace.”
“We believe that this clearance from the FDA validates the progress QuantRx has made developing its technology to meet market demand.”